Alzheimer Disease Clinical Trials in Maitland, Florida
10 studies are recruiting for alzheimer disease in Maitland, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.
- Stage
- Phase 2
- Ages
- 55 and older
- Site
- K2 Medical Research, Maitland, Florida
- Locations
- 71 in total
- Run by
- Intra-Cellular Therapies, Inc.
-
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of…
- Stage
- Phase 1
- Ages
- 50 to 85
- Site
- K2 Medical Research, LLC, Maitland, Florida
- Locations
- 10 in total
- Run by
- Eli Lilly and Company
-
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
The main purpose of this study is to determine if participants who previously took donanemab get clinical benefit when they receive annual doses. For each participant, the study will last up to 2.5 years and will include 6 visits.
- Stage
- Phase 3
- Ages
- 55 and older
- Site
- K2 Medical Research ORLANDO, Maitland, Florida
- Locations
- 62 in total
- Run by
- Eli Lilly and Company
-
[18F]PI-2620 Phase 3 Histopathological Study
This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after de…
- Stage
- Phase 3
- Ages
- 50 and older
- Site
- K2 Medical Research, Maitland, Florida
- Locations
- 25 in total
- Run by
- Lantheus Biosciences Ltd.
-
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the …
- Stage
- Phase 1
- Ages
- 18 to 85
- Site
- K2 Medical Research, Maitland, Florida
- Locations
- 18 in total
- Run by
- Eli Lilly and Company
-
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.
- Stage
- Phase 3
- Ages
- 55 to 90
- Site
- Local Institution - 1622, Maitland, Florida
- Locations
- 162 in total
- Run by
- Bristol-Myers Squibb
-
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
The purpose of this Master Protocol is to support multiple studies looking at safety and tolerability of different drugs in healthy participants and participants with Alzheimer's disease, and if they remove clumps of protein (amyloid plaque) in the brain in participants with Alzheimer's Disease. Pa…
- Stage
- Phase 1
- Ages
- 18 to 85
- Site
- K2 Medical Research, Maitland, Florida
- Locations
- 18 in total
- Run by
- Eli Lilly and Company
-
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
- Stage
- Phase 2
- Ages
- 55 to 90
- Site
- ClinCloud, Maitland, Florida
- Locations
- 77 in total
- Run by
- Celgene
-
A Study of LY3439539 in Participants With Alzheimer's Disease
The purpose of this study is to see how LY3439539 affects certain proteins found in the spinal fluid of participants with Alzheimer's disease. Participation in the study will last approximately 9 months with visits about once a month.
- Stage
- Phase 1
- Ages
- 50 to 85
- Site
- K2 Medical Research, Maitland, Florida
- Locations
- 15 in total
- Run by
- Eli Lilly and Company
-
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). …
- Stage
- Phase 1
- Ages
- 45 to 85
- Site
- K2 Medical Research, Maitland, Florida
- Locations
- 13 in total
- Run by
- Eli Lilly and Company
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.